At a glance
A growth-hormone-derived fragment investigated for effects on fat metabolism.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The literature includes laboratory work and weight-related clinical investigations. Study design, formulation and the size of the observed effect matter more than a general “fat-loss peptide” label.[10][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of AOD-9604.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.667 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 300 mcg | 18 units (0.18 mL) |
| Weeks 5–12 | 500 mcg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥10 for better accuracy. Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support reduction of fat mass and enhance fat oxidation over time[1][4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 300–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.667 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 300 mcg daily for Weeks 1–4; increase to 500 mcg for Weeks 5–12 as tolerated.
- Target: 500 mcg daily by Week 5 and maintain through cycle completion.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Morning administration (fasted) is common; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[7].
- Clean the vial stopper and skin with alcohol; allow to dry completely[8].
- Pinch a skinfold; insert the needle at 90° (or 45° if very little subcutaneous fat) into subcutaneous tissue[7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[13].
- Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy[8].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).
-
Peptide Vials (AOD-9604, 5 mg each):
- 8 weeks ≈ 5 vials
- 12 weeks ≈ 8 vials
- 16 weeks ≈ 11 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- 16 weeks (11 vials): 33 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 04
Research publication
Endocrinology (OUP) — Effects of hGH and AOD9604 on lipid metabolism in obese mice; β‑adrenergic pathway mechanisms (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
Creative Peptides — Peptide stability and shelf life; reconstituted solution storage guidelines (opens in a new tab)www.creative-peptides.com
Back to overview ↑ - 07
- 08
Source document
Olympia Pharmacy — How to administer a subcutaneous injection; site rotation and hygiene (opens in a new tab)www.olympiapharmacy.com
Back to overview ↑ - 10
Source document
Gastroenterology — Drug treatment of the overweight patient; AOD‑9604 RCT summary and clinical efficacy (opens in a new tab)www.gastrojournal.org
Back to overview ↑ - 11
- 12
Source document
DrugBank — AOD9604 drug summary; mechanism of action, bone and metabolic effects (opens in a new tab)go.drugbank.com
Back to overview ↑ - 13
Public health resource
CDC — Vaccine administration: subcutaneous route; no aspiration required (opens in a new tab)www.cdc.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.